Intellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ER

The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly meet tomorrow to review and discuss two opioid drug applications.

Morning session: Esteve Pharmaceuticals S.A.’s tramadol and celecoxib, a combination of an opioid and NSAID for the management of acute pain.

Afternoon session: Intellipharmaceutics International’s (OTC:IPCIF -13.1%) extended-release oxycodone for the management of moderate-to-severe pain.

Meeting materials 

https://seekingalpha.com/news/3531749-intellipharmaceutics-down-13-ahead-of-ad-com-meeting-on-oxycodone-er